RESEARKA

By contrast, the findings from Correia-Melo et al. present a tension within the preclinical evidence base. While rapamycin conferred clear functional benefits in preventing frailty, its failure to impact inflammaging or lifespan in nfκb1 −/− mice suggests that its efficacy may be contingent on the specific pathological context. This study's results indicate that the therapeutic window and target pathways for rapamycin in cardiometabolic aging may differ from those implicated in pure longevity interventions, underscoring the complexity of translating preclinical findings to broad clinical application.

Citation Support

• source_1 Mandrioli 2023
• source_2 Lin 2022
• source_3 Moel 2025
• source_4 Gkioni 2025
• source_5 Zhou 2024